Petros Pharmaceuticals (NASDAQ:PTPI) Releases Earnings Results

Petros Pharmaceuticals (NASDAQ:PTPI) posted its quarterly earnings results on Monday. The company reported ($2.17) earnings per share for the quarter, reports. Petros Pharmaceuticals had a negative return on equity of 97.67% and a negative net margin of 181.87%. The company had revenue of ($0.36) million for the quarter.

Petros Pharmaceuticals Stock Performance

Petros Pharmaceuticals stock opened at $0.93 on Thursday. Petros Pharmaceuticals has a fifty-two week low of $0.90 and a fifty-two week high of $9.54. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.02 and a quick ratio of 2.71. The stock’s fifty day moving average is $1.43 and its two-hundred day moving average is $1.43.

Analyst Upgrades and Downgrades

Separately, Maxim Group began coverage on shares of Petros Pharmaceuticals in a report on Friday, December 8th. They issued a “buy” rating and a $4.00 target price for the company.

Institutional Trading of Petros Pharmaceuticals

Large investors have recently modified their holdings of the business. Renaissance Technologies LLC acquired a new position in Petros Pharmaceuticals in the 2nd quarter valued at about $34,000. Virtu Financial LLC acquired a new stake in shares of Petros Pharmaceuticals during the fourth quarter worth $35,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Petros Pharmaceuticals in the second quarter valued at $47,000. Vanguard Group Inc. increased its stake in Petros Pharmaceuticals by 114.8% in the third quarter. Vanguard Group Inc. now owns 255,914 shares of the company’s stock valued at $131,000 after purchasing an additional 136,773 shares during the last quarter. Finally, BlackRock Inc. increased its stake in Petros Pharmaceuticals by 880.2% in the first quarter. BlackRock Inc. now owns 191,715 shares of the company’s stock valued at $300,000 after purchasing an additional 172,156 shares during the last quarter. 12.34% of the stock is currently owned by institutional investors and hedge funds.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).